Business Context and Reporting Period
This Form 8-K, dated January 5, 2018, reports on material definitive agreements entered into by Inpixon (the "Company"). The filing details a registered direct offering of common stock and warrants, alongside amendments to existing debt instruments. The closing of the securities sale occurred on January 8, 2018.
Key Financial Metrics and Transaction Details
- Offering Proceeds: The Company sold 17,994,359 shares of common stock at $0.177 per share, generating aggregate gross proceeds of approximately $3.2 million.
- Net Proceeds: After deducting placement agent fees (8.0%) and expenses, net proceeds are expected to be approximately $2.8 million.
- Warrants Issued: Warrants to purchase up to 17,994,359 shares were issued concurrently. The exercise price is $0.22 per share, subject to anti-dilution adjustments with a floor of $0.10.
- Existing Debt:
- 8% Senior Secured Convertible Debentures: Principal amount of $1,004,719.
- Convertible Promissory Note: Principal amount of $1,745,000.
- Use of Proceeds: General corporate purposes, including business development, capital expenditures, working capital, and general and administrative expenses.
Material Changes and Agreements
The filing outlines significant changes to the Company's capital structure and debt terms:
- Securities Purchase Agreement: Established a registered direct offering with a "leak-out" agreement restricting investors from selling 35% of the trading volume on January 9, 2018.
- Debenture Amendment: The Third Amendment Agreement allows the Debenture Holder to convert the $1,004,719 principal into common stock after the Company files an amendment to increase authorized shares (deadline: February 15, 2018). Failure to reserve 150% of shares for conversion by this date constitutes an Event of Default.
- Note Amendment: The Waiver and First Amendment Agreement adjusted the conversion price of the $1,745,000 Note to $0.45 (subject to a 70% of closing bid price provision and a $0.10 floor). The right to convert was waived until six months after the effective date.
- Shareholder Approval Requirement: The Company must obtain shareholder approval for the issuance of Warrant Shares and the increase in authorized shares by February 15, 2018. Until approval is received, the Company is restricted from issuing additional common stock or equivalents.
Guidance, Risks, and Contingencies
- Contingency on Shareholder Approval: The exercisability of the Warrants and the conversion of the Debenture are contingent upon shareholder approval of an amendment to the Articles of Incorporation to increase authorized shares. If not obtained by February 15, 2018, the Company must call meetings every 45 days until approval is secured.
- Dilution Risk: Warrants include anti-dilution provisions that reduce the exercise price to the "Base Share Price" (minimum $0.10) if the Company issues stock at a lower price.
- Default Risk: Failure to reserve sufficient shares for the Debenture and Note conversions by the February 15, 2018 deadline will trigger an Event of Default.
- Forward-Looking Statements: The Company cautions that actual results may differ from expectations regarding the completion of the sale and the use of proceeds.
Investor Verification Checklist
- Verify the status of the shareholder meeting scheduled for or prior to February 15, 2018, to approve the increase in authorized shares.
- Confirm the final net proceeds received after all offering expenses are settled.
- Monitor the Company's ability to maintain the required 150% share reserve for the Debenture and Note conversions to avoid an Event of Default.
- Review the impact of the "leak-out" agreement on stock liquidity and trading volume following January 9, 2018.
- Assess the potential dilution impact from the 17,994,359 warrants and the conversion of existing debt instruments.